Acumen Pharmaceuticals Net Income
| ABOS Stock | USD 2.60 0.19 6.81% |
As of the 1st of February, Acumen Pharmaceuticals shows the Downside Deviation of 4.71, mean deviation of 4.21, and Risk Adjusted Performance of 0.0591. Acumen Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Acumen Pharmaceuticals variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Acumen Pharmaceuticals is priced correctly, providing market reflects its regular price of 2.6 per share. Please also double-check Acumen Pharmaceuticals total risk alpha, which is currently at 0.1206 to validate the company can sustain itself at a future point.
Acumen Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Acumen Pharmaceuticals' valuation are provided below:Gross Profit | Market Capitalization | Enterprise Value Revenue 89.674 | Revenue | Earnings Share (2.21) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -92.1 M | -87.5 M | |
| Net Loss | -38.6 M | -40.5 M | |
| Net Loss | -92.1 M | -87.5 M | |
| Net Loss | (1.96) | (2.06) |
Acumen | Net Income | Build AI portfolio with Acumen Stock |
The evolution of Net Income for Acumen Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Acumen Pharmaceuticals compares to historical norms and industry peers.
Latest Acumen Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Acumen Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Acumen Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Acumen Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Acumen Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Acumen Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (102.33 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Acumen Net Income Regression Statistics
| Arithmetic Mean | (33,184,964) | |
| Coefficient Of Variation | (114.91) | |
| Mean Deviation | 32,781,130 | |
| Median | (7,907,000) | |
| Standard Deviation | 38,133,252 | |
| Sample Variance | 1454.1T | |
| Range | 95M | |
| R-Value | (0.79) | |
| Mean Square Error | 585T | |
| R-Squared | 0.62 | |
| Significance | 0.0002 | |
| Slope | (5,959,753) | |
| Total Sum of Squares | 23266.3T |
Acumen Net Income History
Other Fundumenentals of Acumen Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Acumen Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Acumen Pharmaceuticals is extremely important. It helps to project a fair market value of Acumen Stock properly, considering its historical fundamentals such as Net Income. Since Acumen Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Acumen Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Acumen Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Acumen introduce new products? Factors like these will boost the valuation of Acumen Pharmaceuticals. If investors know Acumen will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Acumen Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Acumen Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Acumen Pharmaceuticals' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Acumen Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Acumen Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Acumen Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Acumen Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Acumen Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Acumen Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Acumen Pharmaceuticals.
| 11/03/2025 |
| 02/01/2026 |
If you would invest 0.00 in Acumen Pharmaceuticals on November 3, 2025 and sell it all today you would earn a total of 0.00 from holding Acumen Pharmaceuticals or generate 0.0% return on investment in Acumen Pharmaceuticals over 90 days. Acumen Pharmaceuticals is related to or competes with Inovio Pharmaceuticals, Opus Genetics, Agenus, Alector, Seer, Seres Therapeutics, and Fate Therapeutics. Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treat... More
Acumen Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Acumen Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Acumen Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.71 | |||
| Information Ratio | 0.0622 | |||
| Maximum Drawdown | 31.48 | |||
| Value At Risk | (7.18) | |||
| Potential Upside | 9.94 |
Acumen Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acumen Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Acumen Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Acumen Pharmaceuticals historical prices to predict the future Acumen Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0591 | |||
| Jensen Alpha | 0.3828 | |||
| Total Risk Alpha | 0.1206 | |||
| Sortino Ratio | 0.0815 | |||
| Treynor Ratio | 0.407 |
Acumen Pharmaceuticals February 1, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0591 | |||
| Market Risk Adjusted Performance | 0.417 | |||
| Mean Deviation | 4.21 | |||
| Semi Deviation | 4.52 | |||
| Downside Deviation | 4.71 | |||
| Coefficient Of Variation | 1439.29 | |||
| Standard Deviation | 6.17 | |||
| Variance | 38.07 | |||
| Information Ratio | 0.0622 | |||
| Jensen Alpha | 0.3828 | |||
| Total Risk Alpha | 0.1206 | |||
| Sortino Ratio | 0.0815 | |||
| Treynor Ratio | 0.407 | |||
| Maximum Drawdown | 31.48 | |||
| Value At Risk | (7.18) | |||
| Potential Upside | 9.94 | |||
| Downside Variance | 22.2 | |||
| Semi Variance | 20.45 | |||
| Expected Short fall | (4.91) | |||
| Skewness | 1.92 | |||
| Kurtosis | 8.06 |
Acumen Pharmaceuticals Backtested Returns
Acumen Pharmaceuticals appears to be very risky, given 3 months investment horizon. Acumen Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.074, which signifies that the company had a 0.074 % return per unit of risk over the last 3 months. We have found thirty technical indicators for Acumen Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please makes use of Acumen Pharmaceuticals' Risk Adjusted Performance of 0.0591, downside deviation of 4.71, and Mean Deviation of 4.21 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Acumen Pharmaceuticals holds a performance score of 5. The firm shows a Beta (market volatility) of 1.03, which signifies a somewhat significant risk relative to the market. Acumen Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Acumen Pharmaceuticals is expected to follow. Please check Acumen Pharmaceuticals' skewness, and the relationship between the value at risk and day median price , to make a quick decision on whether Acumen Pharmaceuticals' price patterns will revert.
Auto-correlation | 0.45 |
Average predictability
Acumen Pharmaceuticals has average predictability. Overlapping area represents the amount of predictability between Acumen Pharmaceuticals time series from 3rd of November 2025 to 18th of December 2025 and 18th of December 2025 to 1st of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Acumen Pharmaceuticals price movement. The serial correlation of 0.45 indicates that just about 45.0% of current Acumen Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.45 | |
| Spearman Rank Test | -0.19 | |
| Residual Average | 0.0 | |
| Price Variance | 0.09 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Acumen Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Acumen Pharmaceuticals reported net income of (102.33 Million). This is 129.98% lower than that of the Biotechnology sector and 246.09% lower than that of the Health Care industry. The net income for all United States stocks is 117.92% higher than that of the company.
Acumen Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acumen Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acumen Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acumen Pharmaceuticals by comparing valuation metrics of similar companies.Acumen Pharmaceuticals is currently under evaluation in net income category among its peers.
Acumen Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Acumen Pharmaceuticals from analyzing Acumen Pharmaceuticals' financial statements. These drivers represent accounts that assess Acumen Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Acumen Pharmaceuticals' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Enterprise Value | 532.1M | 136.5M | 89.3M | 97.3M | 111.9M | 106.3M |
Acumen Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Acumen Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Acumen Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Acumen Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Acumen Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Acumen Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Acumen Pharmaceuticals' value.| Shares | Hudson Bay Capital Management Lp | 2025-06-30 | 825 K | Two Sigma Advisers, Llc | 2025-06-30 | 426.3 K | Geode Capital Management, Llc | 2025-06-30 | 396.6 K | Goldman Sachs Group Inc | 2025-06-30 | 334.7 K | Blackrock Inc | 2025-06-30 | 292 K | Ikarian Capital, Llc | 2025-06-30 | 265.8 K | Y-intercept (hong Kong) Ltd | 2025-06-30 | 250.8 K | Renaissance Technologies Corp | 2025-06-30 | 246.6 K | Two Sigma Investments Llc | 2025-06-30 | 200.8 K | Ra Capital Management, Llc | 2025-06-30 | 14.9 M | Sands Capital Ventures, Llc | 2025-06-30 | 3.4 M |
Acumen Fundamentals
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.42 | ||||
| Current Valuation | 72.92 M | ||||
| Shares Outstanding | 60.57 M | ||||
| Shares Owned By Insiders | 7.32 % | ||||
| Shares Owned By Institutions | 64.74 % | ||||
| Number Of Shares Shorted | 599.67 K | ||||
| Price To Book | 1.81 X | ||||
| Price To Sales | 538.78 X | ||||
| Gross Profit | (118.93 M) | ||||
| EBITDA | (98.08 M) | ||||
| Net Income | (102.33 M) | ||||
| Cash And Equivalents | 189.91 M | ||||
| Cash Per Share | 4.69 X | ||||
| Total Debt | 29.7 M | ||||
| Current Ratio | 37.21 X | ||||
| Book Value Per Share | 1.54 X | ||||
| Cash Flow From Operations | (86.22 M) | ||||
| Short Ratio | 2.92 X | ||||
| Earnings Per Share | (2.21) X | ||||
| Price To Earnings To Growth | (0.23) X | ||||
| Target Price | 7.0 | ||||
| Number Of Employees | 61 | ||||
| Beta | 0.24 | ||||
| Market Capitalization | 169 M | ||||
| Total Asset | 238.99 M | ||||
| Retained Earnings | (325.13 M) | ||||
| Working Capital | 150.7 M | ||||
| Net Asset | 238.99 M |
About Acumen Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acumen Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acumen Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acumen Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.